CD4 and myeloid sarcoma: Interestingly, fingolimod-treated relapsed MS patients showed greater percentages of CD4+ TCM (and naïve cells) but not TEM, suggesting that CD4+ TCM may be involved in promoting relapses following fingolimod treatment in MS patients [192].